▎WuXiEdited by Kant Content Team

On November 1, Huahai Pharmaceutical announced that its subsidiary, Huaota, had received approval from New Zealand's Medicines and Medical Devices Safety Authority (referred to as "MEDSAFE") and the Health and Disability Ethics Committee (referred to as "HDEC") to conduct a Phase 1 clinical trial of the HB0056 injection in New Zealand.HB0056It is a bispecific antibody that simultaneously targets TSLP and IL-11, with the proposed indication being asthma.According to the announcement by Huahai Pharmaceutical, currently, there are no other bispecific antibodies targeting both TSLP and IL-11 that have entered clinical trials globally.

Studies show that TSLP is closely related to the occurrence of allergic diseases such as atopic dermatitis, asthma, and chronic sinusitis, and has been clinically proven to be an effective target for low Th2-type asthma (about 40% of the population).IL-11 is upregulated in invasive pulmonary fibroblasts.

HB0056 is a recombinant humanized IgG1 bispecific antibody that simultaneously targets human thymic stromal lymphopoietin (TSLP) and interleukin-11 (IL-11).HB0056 can simultaneously block the IL-11 and TSLP signaling pathways, inhibiting their biological activity. Additionally, this product can suppress the expression of fibrosis-related genes in MRC-5 cells (human embryonic lung fibroblasts) and has demonstrated the potential for synergistic effects of dual-target inhibition during the research process.。

According to the announcement by Huahai Pharmaceutical, in vivo pharmacodynamic studies have shown that HB0056 demonstrates superior improvement in serum OVA-specific IgE, eosinophil counts in BALF lavage fluid, and eosinophil infiltration in lung tissue. It also exhibits the potential for synergistic efficacy of dual-target therapy in asthma treatment.